摘要
目的探讨吉非替尼单药二线治疗非小细胞肺癌的临床疗效及毒副反应。方法经病理学确诊的非小细胞肺癌患者70例(鳞癌30例,腺癌40例),均给予口服吉非替尼(250 mg/d),并观察治疗效果及药物毒副反应。结果全组70例患者中,CR 5例、PR 14例、SD 28例、PD 23例,总有效率27.14%,疾病控制率67.14%。腺癌总有效率及疾病控制率高于鳞癌(χ2=5.036、6.994;P=0.024、0.008)。主要毒副反应大多为轻度皮疹、腹泻、疲乏、肝功能异常等。结论吉非替尼二线治疗非小细胞肺癌具有一定疗效,毒副反应也可耐受;对腺癌的疗效明显优于鳞癌。
Objective To investigate the clinical efficacy and toxic and adverse effects of gefitinib in the second-line treatment of non-small cell lung cancer. Methods There were 70 cases of non-small cell lung cancer （30 cases of squamous cell carcinoma and 40 cases of adenocarcinoma） given gefitinib through oral administration （250 mg/d）, and the clinical efficacy and toxic and adverse effects were observed. Results In the 70 cases, there were 5 cases of complete remission （CR）, 14 cases of partial remission （PR）, 28 cases of stable disease （SD）, and 23 cases of progressive disease （PD）. The total effective rate was 27.14%, and the disease control rate was 67.14%. The total effective rate and disease control rate of adenocarcinoma were higher than those of squamous cell carcinoma （χ2=5.036, 6.994;P=0.024, 0.008）. The main toxic and adverse effects were mild rash, diarrhea, fatigue, and abnormal liver function. Conclusion Gefitinib is effective in the second-line treatment of non-small cell lung cancer, and its toxic and adverse effects can be tolerated. Its curative effect for adenocarcinoma is obviously better than squamous cell carcinoma.
出处
《中国现代药物应用》
2014年第16期18-19,共2页
Chinese Journal of Modern Drug Application
关键词
非小细胞肺癌
吉非替尼
鳞癌
腺癌
Non-small cell lung cancer
Gefitinib
Squamous cell carcinoma
Adenocarcinoma
